 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Makerere University Biomedical Research Center |
| Street 1: | Upper Mulago Hill |
| Street 2: | |
| City: | Kampala |
| Province: | |
| Post Code: | |
| Country: | Uganda |
| Phone: | 0782752582 |
| Organization Email: | makbrc.chs@mak.ac.ug |
| Web Site: | http://www.brc.mak.ac.ug |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 80020002620794 |
| Organization Type - Primary: | Academic / Research Institution |
| Organization Type - Secondary: | None |
| Organization Description: | |
| Makerere University Biomedical Research Centre (MakBRC)is a Centre of Excellence of Makerere University in the school of Biomedical sciences. The institution supports biomedical research and fosters translation of such research into innovations. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Research and Development |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 26 - 50 |
| Number of part-time staff who are directly involved with TB: | 51 - 99 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Attendance at a TB related event |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | N/A |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | Uganda |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| The institution supports biomedical research and fosters translation of such research into innovations. |
|
Geographical Reach | |
| Which country is your headquarters located in: | Uganda |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Uganda |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: MakBRC participates in TB care delivery through advocacy and communication and mobilization through special days such as the celebrations of the word TB day in Uganda, special camps among others. during these days, our lab offers free TB testing to participants with signs and symptoms of TB. Drug-Resistant TB: Our laboratories have participated in the National TB drug surveys and support the NTRL/SRL in the new DST method evaluation. Our laboratory was the WHO training center for the TB none non-commercial DST method. Continuously the Mycobacteriology (BSL-3) of the MAKBRC has participated in several TB drug trials including the STREAM2 Trial, and SHINE trial among others. The Same laboratory under MAKBRC has evaluated several diagnostics for NTRL/SRL uptake and roll-out such as the GeneXpert Ultra, Truenat, and GeneXpert XDR. TB-HIV: The majority of the studies that utilize our laboratories are done among people living with HIV (PLHIV). Our laboratory supports TB-HIV through the provision of standard diagnostic and/or DST results which are used to offer better care. Laboratory Strengthening: MAKBRC laboratories, especially the Mycobacteriology laboratory is the backup laboratory for the NTRL/SRL Uganda. This laboratory offers technical support in all diagnostics strengthening activities of the NTRL/SRL, through laboratory and personnel back-up. New Diagnostics: Since the inception of the Mycobacteriology (BSL-3) laboratory in 2008, our laboratory has participated in Diagnostic validation studies including; UrineLAM, Epistem/MolBio, Genedrive, TBLAMP, GeneXpert MTB/ULTRA, BDMax, and all of these made it to the WHO endorsement. Others still under development include Small Membrane Filtration for smear microscopy (SMF), Biopromic LAM (BPLAM), Truenat COMBO for COVID-19/TB, M10 MDR-TB cartridge from SB Biosensor, Sanity MTB/M/XDR, USTAR MTB diagnostics among others. Among the new non-sputum-based diagnostics or triage tests, our laboratory is participating in Multi-country studies for AI-based triage Audio testing (CAGETB) study, novel qPCR stool-based diagnostic for TB in children and PLHIV (STOOL4TB) and Predicting the Future Incipient TB (PreFIT) studies aiming at detecting subclinical TB and testing for risk of progression to active disease. Our laboratory also participates in network diagnostic studies for R2D2 and FEND groups. New TB Drugs: For several years, our laboratory has been the laboratory of choice for TB clinical trials. Such Clinical trials include; PROMPT, The TB Alliance trials of NC-005, NC-006, NC-008 (SimpliciTB), and currently considered for NC-009. The STREAM2 and SHINE trials. Our laboratory is a Network lab for the AIDS clinical trial group (ACTG/IMPAACT) trials [P1108, IMPAACT 2020, A5300B, IMPAACT 2003B / A5300B, A5349, and A5274. The TMC2017-C211 and currently participating in the PanACEA trial (Step2c). New TB Vaccines: The Mycobacteriology (BSL-3) Laboratory of the MAKBRC was constructed in 2008 with full funding from the AERAS Global TB Vaccine Foundation with the capacity to participate in new TB vaccine trials. This facility still maintains the standards to participate in the new vaccine trials. i.e. maintains ISO 15189 College of American Pathologist Accreditation 2014 to date. Fundamental Research: Our facilities exist with three core objectives; 1) to train students and researchers in mycobacteriology and other communicable and none non-communicable diseases, 2) To conduct cutting-edge research and 3) to serve the community. From the above descriptions and more, it is evident that our laboratories contribute significantly to fundamental Research. For example, our laboratory is a Center of Excellence (CoE) for Genomics research with basic and advanced technologies including but not limited to the latest Whole Genome Sequencing (WGS) techniques, fundamental drug, and gene target methods, novel adjuncts TB therapy research such as Mycobacteriophage research among others. Research: Research is one of our core objectives and our laboratory is the main contributor to the research-generated knowledge in Mycobacteriology with a main emphasis on Tuberculosis. Of importance to note; Our laboratory has started supporting Post TB Lung Disease (PTLD) research to understand PTLD better. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | August 17, 2023 |
| Last updated: | October 18, 2023 |